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PERSPECTIVE
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Engineering, The College of New Jersey, Ewing, NJ, USA; dWillem Kolff Foundation (Kampen, NL), Zwolle, The Netherlands; eDepartments of
Biomedical Engineering, and of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, Utah, USA
ABSTRACT
Introduction: Biomedical-engineering (BME) plays a major role in modern medicine. Many BME-based
assets have been brought to clinical translation in the twentieth century, but translation currently
stagnates. Here, we compare the impact of past and present scientific, economic and societal climates
on the translation of BME-based assets, in order to provide the BME-community with incentives to
address current stagnation.
Areas covered: In the twentieth century, W.J. Kolff brought kidney dialysis, the total artificial heart,
artificial vision and limbs to clinical application. This success raises the question whether Kolff and other
past giants of clinical translation had special mind-sets, or whether their problem selection, their
training, or governmental and regulatory control played roles. Retrospective analysis divides the impact
of BME-based assets to clinical application into three periods: 1900–1970: rapid translation from bench-
to-bedside, 1970–1990: new diseases and increased governmental control, and the current translational
crisis from 1990 onward.
Expert opinion: Academic and societal changes can be discerned that are concurrent with BME’s
translational success: mono-disciplinary versus multi-disciplinary training, academic reward systems
based on individual achievements versus team achievements with strong leadership, increased govern-
mental and regulatory control, and industrial involvement. From this, recommendations can be derived
for accelerating clinical translation of BME-assets.
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Valorization has become an integral part of science and engi-
neering, and academic knowledge transfer is no longer optional
anymore, but mandatory. Universities are viewed as key players
in entrepreneurial innovation, following a worldwide paradigm
shift in the overall scientific, economic and societal climate [1–3].
The academic discipline of biomedical engineering (BME) covers
a vast spectrum of highly different disciplines. BME connects its
centric fields and diverse disciplines through the application of
engineering principles and design concepts with medicine and
biology for health-care purposes, to produce a mission that is
diagnostically, prophylactically and therapeutically focused.
Traditionally, BME is positioned at the forefront of healthcare
innovation. Typical BME areas of research include biomechanical,
clinical, tissue, genetic and neural engineering, biomaterials and
materiobiology, implant and device design, artificial organs and
transplantation medicine, nanomedicine, bioinstrumentation,
imaging diagnostics and robotic surgery, application of electro-
magnetic fields, lasers and ultrasound, and big data analysis [4].
BME therewith closes the gap between engineering and medi-
cine and nowadays plays a crucial role in what is called ‘healthy
ageing’, a contradictio in terminis meant to express the universal
desire of human beings to enjoy a high quality of life for the
longest possible period of time and then die within the shortest
possible period of morbidity and decline from onset of disease
till death (Figure 1). Whereas death hardly influences health-care
costs, effective compression of the ‘morbidity and decline period’
reduces health-care expenditures, forming a growing economic
burden in modern societies [5].
Downward clinical translation is defined as a process of mov-
ing basic academic research to clinical application. Others view
clinical translation as an entrepreneurial process. Regardless of
the exact definition, successful downward clinical translation of
BME assets has occurred over the last 100 years, beginning slowly
in the 1920s and more rapidly in the post-WWII period. This age
of translation was arguably led by the Dutchman W.J. Kolff
(1911–2009), bringing diverse innovations like kidney dialysis,
the total artificial heart (TAH), artificial vision and limbs to clinical
application [7]. BME sustained a high level of successful clinical
translation apparently until the turn of the twenty-first century,
that directly affected the ‘morbidity and decline compression’
(Figure 1). Notwithstanding ongoing technological advances in
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instrumentation, rehabilitation, medical device designs, new
diagnostics and imaging capabilities, a series of articles in various
medical journals [8–14] maintain that innovation has stagnated,
and translation of BME assets from laboratory to bedside has
diminished significantly, especially innovation and translation
directly geared toward impacting disease, morbidity, and
decline. The most cited evidence that translation is stagnating
follows from the number of new truly innovative, first-in-class
drugs coming to market from a high in the late 1980s and early
1990s, each following decade seeing less and less drug approvals
[15]. Another measure is fewer patents for drugs and devices [16]
in spite ofmore basic research, greater funding, larger databases,
and genomic developments [17–21].
This reduction in medical innovation performance bench-
marks of BME, raises the question whether Kolff and the other
past giants of downward clinical translation had a special
mind-set that allowed them to be more creative in translating
assets of their research and development processes to clinical
practice, whether it was the types of problems they worked
on, the mono-disciplinary training of them and their team
members or less governmental oversight and a more lenient
regulatory system that allowed them to emerge as giants of
downward clinical translation.
In order to answer these questions, we present a historical
review of past innovations in biomedical engineering, how
they transpired and were translated to accepted, routine clin-
ical applications. Comparing the past with the present, recom-
mendations are made on how to speed up downward clinical
translation of BME assets.
2. A historical perspective
2.1. Introduction
A significant recognition of the importance of BME, based on
its historical impact, was the foundation in 2000 of the
National Institute of Biomedical Imaging and Bioengineering
and the American Institute for Medical and Biological
Engineering seeking to showcase BME assets, select global
leaders as honorary Fellows, and advocate BME’s leading role
in medicine at governmental levels [22]. The impact of BME’s
contributions to clinical applications over the last century can
be divided into three distinct periods each with their own
context, motivations, and achievements (Table 1).
2.2. The age of the giants (1900–1970)
Translational medicine from 1900 to the 1970s represented
a remarkable era in biomedical scientific progress when vision-
ary and forceful personalities in research medical centers held
sway over talented teams, driving their personal visions with
determination, passion and unrelenting focus to clinical trials.
Therefore, we call this period the ‘age of the giants’. These
‘giants’ typically had access to financial support including
governmental funding and conducted local clinical trials with
relatively little oversight other than from their own ethical
judgment or institutional policy.
Diabetes research produced an early multi-disciplinary team
effort in the isolation and production of insulin. The Connaught
Laboratories at the University of Toronto beganwork in 1920 and
within 2 years produced the modern treatment for diabetes. In
1929, they began research into heparin, releasing a protocol
based on bovine and porcine intestines within 6 years [23].
Tuberculosis research, as another example, consumed consider-
able efforts resulting in streptomycin in 1946.
Control of untreatable diseases emerged in the 1950s to
loom large in the public domain, providing an optimism for
improving human health unseen in previous times.
Traditional children’s diseases were eliminated with the
‘baby shots’ series. Salk’s (1914–1995) efforts in treating
polio earned him worldwide fame. Nine years of focused
Article highlights
● Retrospective analysis divides the impact of BME-based assets to
clinical application into three periods: 1900–1970: rapid translation
from bench-to-bedside, 1970–1990: new diseases and increased gov-
ernmental control, and the current translational crisis from 1990
onward.
● Direly needed, direct involvement of clinicians in different stages of
downward clinical translation decreases with risks of misdirected
innovative efforts and waste of resources.
● Past successes of the multi-disciplinary teams in the age of the giants
have led to multi-disciplinary education programs, but multi-
disciplinary trained researchers do not replace the absence of clin-
icians in a team, nor does multi-disciplinary training provide specia-
lists with the necessary deep knowledge and expert insight in their
specific domain.
● While acknowledging the need for patient protection in human
clinical trials, oversight should be more receptive and adaptive to
needed innovation, risk-reward features of human introduction, and
less antagonistic towards clinical translation.
● Clinical translation goes hand-in-hand with the progression of basic
scientific knowledge, but making clinical translation central in guid-
ing new developments, may have become a limiting factor for
innovation.
● Partnering of industry and academia is needed for downward clinical
translation, but industry must be more willing acknowledge academic
importance to publishing, while academia must endorse the indus-
trial responsibly of protecting important discoveries with patents.
● First signs of academic and societal changes can be discerned,
including new violations of governmental oversight and human
ethical constraints, that may herald the end of the current clinical
translational crisis.
Figure 1. The goals of healthy aging and the challenges presented to BME are to
elongate the human health-span, while compressing the period of morbidity and
decline between the onset of disease till death (adapted from Hubert et al. [6]).
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research with a talented team resulted in Salk’s ‘killed’ vac-
cine, delivered in three injections. Sabin followed with his
attenuated vaccine more easily delivered on a sugar cube
[24]. Kolff built the first clinically successful dialysis device in
The Netherlands during WWII (1939–1945) [25]. His simple
rotating drum design, based on cellophane tubing, was repli-
cated in its original form and in the later robust Brigham-Kolff
machine (1949). Results from these two designs between
1949 and 1953 prompted the medical community to accept
dialysis as a viable treatment for acute kidney failure. Kolff
emigrated to the USA in 1950 and designed a more user-
friendly and less expensive dialysis design: the Twin Coil. Well
into the 1960s, Baxter Travenol eventually produced the Twin
Coil in the thousands. Kolff, who pursued dialysis designs to
improve the treatment of kidney failure for the rest of his
career, subsequently widened his interest into cardiovascular
device development [26] with engineering teams from
around the world. He controlled laboratories and funding
with his strong personality and organizational skills. Kolff
had an implicit faith in technology-based medical treatment.
His entire career was devoted to device development, earn-
ing him the title ‘the Father of Artificial Organs’ [7].
Expertise in cardiothoracic and transplantation surgery
advanced rapidly with the advent of the heart-lung bypass
machine. Introduction of immuno-suppressant drugs in the
1970s allowed transplantation of hearts and kidneys. Lillehei
(1918–1999) pioneered open heart surgery and trained an
entire generation of surgeons at the University of Minnesota.
Lillehei worked closely with a range of specialists, including
electrical engineers [27]. Bakken produced a range of instru-
ments and maintained others, when Lillehei asked him to
design and build an external pacemaker for his patients. The
first wearable external pacemaker began a new page in
Bakken’s career. He and his brother went from working in
their garage to founding Medtronic [28]. Similarly, Houston
became a center for cardiothoracic surgery in the 1960s.
DeBakey (1908–2008) developed left ventricular assist
devices (LVAD’s), rotary pumps, Dacron vascular grafts, and
other assist devices at the Baylor School of Medicine, USA
[29]. He had a similar vision as Lillehei and Kolff: create
multi-disciplinary teams of mono-disciplinary trained engi-
neers and clinicians to work in concert and provide them
with clearly defined, clinical problems to address.
The world would look different without total hip replace-
ment brought to widespread clinical use and success by
Charnley, who was as a British orthopedic surgeon con-
vinced of the need to collaborate with mechanical engineers
and materials scientists to overcome the wear and adverse
tissue reactions resulting from the use of Teflon in his first
prototypes [30]. In 1962, he implanted the first total hip
arthroplasty using high molecular weight polyethylene but
cautiously waited 10 years before announcing success [31].
Around the same time in the 1960s, Brånemark, in Sweden,
developed osseo-integratable materials leading to dental
Table 1. Three distinct historical periods of translating BME assets to clinical applications.
1900–1970
AGE OF THE GIANTS
Rapid translation







Multidisciplinary-trained engineers work in teams on health-related
problems
ACCELERATORS and DECELERATORS
- WWI and WWII
- Visionary leaders with strong organizational abilities
- Multidisciplinary teams of mono-disciplinary trained
engineers and clinicians
- Evolving legislative and bureaucratic
processes
- Increased governmental funding
and IRB oversight
- Emergence of biomedical engineering as a new academic
discipline
- Increasing health care costs consideration
- Strong influence of human medical ethical committees
- Societal resistance to animal use and approval for animal
experiments becoming more difficult
- Strong influence of regulatory agencies on application and
marketing of innovations
- Establishment of a modern health care system and new aging
goals, including cost reduction
- Negative clinical trial outcomes are often not published
- Public-private partnerships act as translational catalysts








-Compression of the morbidity and decline period from the on-set
of disease till death
-Gene therapies
-More basic research on emerging diseases
-Generic drug development
ROLE of BIOMEDICAL ENGINEERING
-Dialysis delivery






-Total artificial heart (TAH)
-Refinement of medical devices
utilizing new materials
-New medical imaging techniques
and devices
-Multi-disciplinary trained engineers become key-players in
healthcare technology development
-Transition of focus from organ systems to cellular and molecular
levels
-More advanced, basic research requirements
-Development of materiobiology, aiming to control human biology
using materials
-Emphasis on supporting technologies like eHealth, 3D-printing,
organs-on-a-chip
-Big data analyzes to reveal factors influential on disease,
morbidity and decline
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implants [32], arguably regarded as the largest innovation in
modern dentistry. In all clinical innovations described above,
multi-disciplinary teams were given considerable freedom
along with funding and equipment, with their sole mission
to resolve a compelling clinical problem.
Most early innovations arising from biomedical engineering
were mechanical in nature and constructed from not too costly,
readily available materials. Importantly, in the post-WWII period,
the USA retained its manufacturing infrastructure intact, with
considerable funds allocated for medical research, as opposed
to a devastated Europe where most funds went to urgent,
immediate clinical services. WWII contributed to significant
advances in surgery, following a tradition that began in WWI
and accelerated research into treating a wide range of diseases
and rehabilitation procedures. Penicillin, for instance, was
brought to clinical application in a record time of 15 years from
its first discovery in 1928 to large-scale use inWWII, during which
infection threatened the lives of many wounded soldiers. Public
support of disease control developed strongly after 1945 and
increased with each further success. Medical centers became
more than a hospital; they were targeted by major philanthropic
foundations, central or federal governments as focal points of
biomedical research and development addressing diverse med-
ical problems. Principal investigators in these early research cen-
ters maintained tight control over administration of treatment
and oversight of research in their individual units, with rapid
feedback coming back from clinical colleagues. This allowed
multiple device prototypes to be developed, tried, refined or
eliminated quickly and with considerable variation, in a manner
unseen today. Kolff, for instance, reported 17 patients with
advanced kidney failure between October 1942 and
September 1945. Sixteen of these 17 patients died during,
directly after or in the days after treatment with different proto-
types of his kidney dialysis device. The first surviving patient #17,
was a 67-year-old woman treated for 11.5 h. She made full
recovery [7,25]. Accordingly, in the age of the giants, new BME
assets resulted from multiple clinical trials after elimination of
flawed designs and rapid refinement of prototypes to address
daunting medical challenges, considered unsolvable before
these innovations.
2.3. Transition: an end to the age of giants (1970–1990)
The 1970s through the 1990s were notable for increased
governmental oversight of new treatments and technologies.
Applicants for federal research funding were required to
demonstrate not just a solution to an insurmountable clinical
problem with a solid scientific/engineering basis, but also
report approvals of institutional IRBs and precise methodolo-
gies on how clinical trials would be orchestrated, types of data
collection and analyses, and how patients were protected
against the risks of experimental therapies. Later, similar poli-
cies and requirements would be applied to increased over-
sight regarding preclinical animal testing. These changes led
to a USA-initiated focus on downward clinical translation and
a resulting perceived hostility toward regulatory bodies (i.e.
US-FDA) and restrictive governmental oversight.
Although governmental oversite increased, this period con-
tinued production of significant devices and pharmaceuticals.
For some, including Kolff, the Holy Grail of technological sup-
port for human health was a total artificial heart (TAH). Others
fiercely resisted the thought of replacing parts of the human
body by machine parts [7]. The many designs for a TAH and
a wider array of LVADs were usually designed as a bridge to
transplantation for desperate patients waiting for a donor
heart. The TAH for these patients was a large, ungainly hospi-
tal-based, device often pneumatically powered to keep
patients alive while awaiting a donor heart. Lighter, and later
ambulatory, LVADs performed the same function and allowed
patient mobility. The technological issues for developing
a TAH independent of the hospital that allowed the patient
to live a reasonably normal life were daunting. The energy
supply system, valve failure, access ports, drivelines, and ubi-
quitous blood coagulation and infection issues were almost
insurmountable challenges. Lastly, preexisting patient morbid-
ities severely limited survival chances, as end-stage heart fail-
ure also meant concomitant, accompanying downstream
organ failure [26,33].
At the same time, pharmaceutical development faced new
challenges. A growing emphasis on cancer research and treat-
ment, beginning in earnest in the late 1960s, with the rise of
the American Cancer Society lobby and USA President Nixon’s
touted ‘War on Cancer’, saw the development of powerful new
tools for research including genetic engineering for RNA repli-
cation and recombinant DNA. Monoclonal antibodies in con-
junction with chemotherapy and radiation treatment allowed
for individualized therapy in several cancer patients [34]. Major
drug companies quickly assimilated all the latest imaging,
computer, and polymerase chain reaction techniques into
research and development pipelines. One appreciable success
was the use of recombinant DNA to produce human insulin
[35]. Another highly visible effort, led by the World Health
Organization, resulted in the virtual elimination of smallpox
by the end of the decade [36]. Other widely used drugs
developed during this period, following the prevention and
control approach, included statins [37] for cholesterol control
and the equally important antihypertensive drugs [38].
The downside of these translational successes were not only
the large expectations among the general public regarding ‘better
living through pharmacy’, ‘healthy aging reaching to old age’, but
also the costs associated with clinical application of BME assets. In
order to reduce patient costs, the large-scale emergence and
availability of generic drugs was promoted. The 1984 Drug Price
Competition and Patent Term Restoration Act enabled generic
drugs proven to exhibit identical bioequivalence to the patented,
approved and exempt from repeating clinical trials. This signifi-
cantly reduced themarket entry costs, once exclusivity rights from
a patented drug expired [39]. More drugs became available to
more people at reduced costs through this pathway [40]. As
a result, traditional and costly pharmaceutical research and devel-
opment efforts would see less market exclusivity, return and
market incentive to subsidize further risky development initiatives.
Therewith, drug innovation and development incentives became
limited. The greatest new product challenge to drug companies
was the growing, almost epidemic, problem of antimicrobial and
anti-tumor drug resistance. The natural selection that occurs in
a changing environment including disease means that eventually,
some type of resistance develops. Seventy-five years of antibiotic
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treatment and overuse finally resulted in selection of naturally
occurring antimicrobial-resistant pathogens, and a perceived end
to the traditional antibiotic armada. This meant that drug compa-
nies, governmental research, and academic/medical institutions
were forced to reconsider basic research and development all over
again to re-address clinical problems thought to be solved dec-
ades prior [18]. However, antimicrobial drug development in this
era no longer provided the attractive financial incentives of past
years to balance development costs and risks of new antibiotics.
Limited clinical first-in-class new antimicrobial offerings are
a result.
Apart from poorly understood, emergent, threatening dis-
eases without a cure taking over the medical innovation spot-
light, these transition years witnessed increased governmental
funding with accompanying patient and animal model ethical
scrutiny. Human (e.g. IRB) oversight and regulatory complex-
ity, both in the USA and Europe, defined the end of the
transition period. The FDA had hegemony in the USA, based
on a long institutional history and authority, dating from 1906.
The European Union also implemented a series of legislative
acts for drugs and devices beginning later in the 1980s. The
Safe Medical Devices Act in the USA of 1990 was a reform of
the original 1976 laws to provide greater public protection by
requiring anyone who marketed medical devices to monitor
and record their patient use and report all adverse events and
failures to the FDA. Such new regulatory burden, established
for proper patient protection, arguably also hindered the pace
of product development and medical innovation.
Cynically, although Kolff might be considered as one of the
most successful translators of BME assets to clinical application,
he arguably also laid the foundation for the end of the age of the
giants. His self-adapted ‘freedom to operate’ with new technol-
ogies implanted into desperate patients suffering life-
threatening diseases, likely indirectly contributed to increased
governmental and institutional oversight. This in turn slowed
further rapid transitions of new ideas from bench-to-bedside
and back. When in 1981, Kolff failed to obtain NIH funding for
his TAH development, he went down his own path. Without NIH
funding and oversight at that time, he took the risk of implanting
the Jarvik-7 TAH heart into a terminally ill patient, gaining con-
siderable notoriety in 1982 with the first TAH implantation into
the elderly American dentist, Barney Clark, suffering end-stage
organ failure associated with congestive heart failure [41].
However, this single, cavalier surgical event attracted consider-
able press attention.
A major ethical question raised after Dr. Clarks’ death after
living 112 days on the TAH, was how a single academic
medical center could ‘experiment’ on a human patient in
a terminal condition, with their basic patient rights protected
only by the local institution. The ethical issues regarding the
nature of such treatment are still being debated. Questions
also arose over whether substantial amounts of money should
be devoted to costly treatments of few and often terminally ill
patients, that provided little chance of long-term success
given the greater need for funding more widely applicable
and affordable new treatments. These questions, both eco-
nomic and ethical, fed into an already evolving legislative
and bureaucratic process, in which NIH, FDA, and USA Public
Health Service were given greater oversight with the aim of
protecting all patients, regardless of federal biomedical
research funding or patient’s desperation and desire for
treatment.
2.4. Translation in crisis (1990-present)
At the end of the transition period, engineering had become
an essential component of the biomedical world and changed
in response to increased public awareness and subsequent
governmental funding of health care and research.
Biomedical research occurred in the postwar period till 1990
with mechanical engineers bringing their expertise to disabled
veterans with lost limbs. Electrical engineers were involved in
heart-related matters with pacemakers. Computer engineers
had a huge impact in relation to software development for
computational modeling. In the early 1990s, an entirely new
multidisciplinary field appeared: biomedical engineering [4,42]
with growing academic interests, formal BME degrees, creden-
tialing and research funding. Multi-disciplinary trained biome-
dical engineers working in teams on human health-related
issues were distinct from predecessor, innovative teams of
dedicated, mono-disciplinary trained specialists, each contri-
buting their own expertise in multi-disciplinary teams, charac-
teristic of the ‘age of the giants’.
In the 1990s, a major transition occurred, prompting BME
to focus on cellular and molecular technologies rather than
solely operating on the level of organ systems, with the
Human Genome Project and the Nobel Prize in Medicine for
Mullis in 1993, rewarding his polymerase chain reaction tech-
nique, as some early prominent and enabling examples of new
innovative tools. New techniques for manipulating and orga-
nizing molecular and cellular systems in biology exploded,
with many future medical benefits promised. Further advances
in bio- and nanotechnologies, tissue engineering, and artificial
organs are ongoing, but require advanced basic research
before translation to clinical application. These together have
led to a new field within biomedical engineering named
‘materiobiology’ [43]. Downward clinical translation of the
assets of these new developments is performed under strong
governmental oversight. Permission for validating preclinical
animal studies is becoming more and more difficult to obtain,
while moreover, animal use is under strong societal scrutiny.
Human clinical trials are closely monitored and regulatory
requirements for marketing new drugs and devices are some-
times close to impossible due to unrealistic requirements on
clinical cohort sizes required for statistically significant benefit
demonstration [44]. This scenario necessarily delays acquisi-
tion of translational evidence required to validate new medical
technologies, increasing research and development costs that
also impact health-care costs, promoting ‘substantial equiva-
lence’ claims for incrementally different new drug and device
introductions, emphasis on generic drugs instead of first-in-
class breakthroughs. These scenarios taken together subse-
quently discourage commercial efforts to start new, higher
risk innovation initiatives. Simultaneously, a growing geriatric
global demography demands healthy aging, yet requires more
and personalized healthcare, all raising health-care costs.
Globally, large patient groups, especially in developing coun-
tries, lack access to the assets of biomedical engineering due
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to their high costs. Orthopedic implants are not seldom used
from one patient into another [45,46] or are locally produced
[47], all to reduce costs and make them more widely available.
New fields of BME such as eHealth, organ-on-a-chip, and 3D-
printing are yielding cost-reductions without becoming visible
as the new and spectacular advances like in the age of the
giants, and lacking a clear impact on disease, morbidity and
decline.
3. Comparing the past and present
3.1. Leadership, team efforts, and academic
individualism
The age of the giants had brilliant, determined and undaunted
leaders, with a cavalier attitude that was almost as important
as their leadership ability in driving projects through the
barriers of their times with self-adapted freedom to operate.
Often stubborn, sometimes even ruthless, they drove them-
selves and their teams to overcome challenges to bring des-
perately needed aid and benefits to their patients. Downward
clinical translation then was more important than innovative
research that aims to publish high-impact papers, often pro-
mising clinical application, but in reality, representing nothing
more than yet another scientific novelty.
University incentives and academic promotional systems
nowadays more and more reward individual achievement
based on published work and fund-raising, rather than team
efforts aimed at translational research, more common to the
age of the giants [8]. Also in academic medical centers,
research is nowadays not always considered to be an econom-
ically viable activity due to the lack of renumeration for clinical
staff time when conducting research compared to generating
patient-driven clinical revenues. Innovative research, the foun-
dation of any translational activity, is often viewed as disrup-
tive to clinical care [12,48]. Nevertheless, clinicians are crucial
for clear definition of the clinical problem to be solved, gui-
dance and evaluation of new designs and solutions proposed.
As a result, the direly needed, direct involvement of clinicians
in different stages of downward clinical translation decreases
with risks of misdirected innovative efforts and waste of
resources [38,49–52].
3.2. Changes in academic training
The age of the giants was characterized by multi-disciplinary
teams of mono-disciplinary trained specialists. A main educa-
tional question for a long time has been how to foster and
institutionalize innovation and enhance the translational pro-
cess [1,53,54]. Past successes of the multi-disciplinary teams in
the age of the giants have inspired and stimulated develop-
ment of diverse multi-disciplinary education programs.
However, multi-disciplinary trained researchers do not replace
the absence of clinicians in a team, nor does multi-disciplinary
training provide specialists with the necessary deep knowl-
edge and expert insight in their specific domain: mono-
disciplinary trained specialists know a lot about almost nothing,
but a multi-disciplinary trained scientist knows almost nothing
about a lot. In modern medical education, the role of science
and engineering in translational medicine is acknowledged by
training physician-scientists or doctor-engineers, but without
filling the deep knowledge and expert insight gap in absence
of mono-disciplinary trained specialists [55–57].
3.3. Governmental oversight
With the accelerating influence on downward clinical transla-
tion of WWI and WWII during which rapidly saving lives was
seemingly more important than human ethical considerations,
the giants may have acted in a way that would nowadays
evokes major ethical concerns. Yet one may wonder at the
same time whether under present-day governmental over-
sight and without Kolff his self-adapted freedom to operate,
kidney dialysis would have ever become the life-saving proce-
dure it now represents globally. Governmental oversight of
human clinical trials and animal experiments is indeed often
portrayed as the single most substantial impediment to clin-
ical translation. While necessarily acknowledging the compel-
ling need for patient protection in human clinical trials,
oversight should be more receptive and adaptive to needed
innovation, risk-reward features of human introduction, and
less antagonistic toward clinical translation [58].
3.4. Types of problems studied
Did the giants ‘pick the low-hanging fruits’, leaving current
generations with clinical problems that are more difficult to
solve? Whereas in hindsight, this is easily said, the problems of
their times were most likely equally complex to solve and
required knowledge that was beyond the horizon of scientific
knowledge of the times. This illustrates how clinical translation
goes hand-in-hand with the progression of the basic scientific
knowledge, of which it cannot always be predicted whether
and when it will turn to use for application. This realization
begs the thought that making clinical translation important
for obtaining research funding and central in guiding new
developments may backfire and have become a limiting factor
for innovation.
3.5. Regulatory requirements and market introduction
Industry is regarded as a necessary partner in fostering
a focused path toward improved product development lead-
ing to clinical translation. Increased industrial cooperation,
sharing of data and resources is essential [59,60]. This partner-
ing is often beyond reach or realization for most academic
researchers who generally know little about how and why
industry decisions are made or can be leveraged for mutual
benefit. Traditionally, universities have been the repository of
basic research and initial innovative processes but not their
maturation; industry must take over prototype development
and testing for validation, regulatory approval, and eventual
manufacturing, bringing the successful product to market in
an economically feasible design, while assuming all risks at
that level. For example, during the age of giants, Kolff devel-
oped his Twin Coil dialysis device exclusively at Cleveland
Clinic and literally had to go shopping to find
a manufacturer with a nearly final design. Moreover, the
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decision to search for an industrial partner was taken out of
his personal ambition to save the lives of his patients, and not
by his scientific or personal financial ambitions or those of
companies and their shareholders. Nowadays, many BME
departments have industrial members who sit on their advi-
sory boards and participate in senior design evaluation.
Funding for industrially oriented undergraduate and graduate
projects is a key part of this relationship. Therewith, industry
has become a much bigger, key player than ever before in
clinical translation. Given their economic incentives as a driver,
industrial partnering requires greater protection for patients
and attention to health-care costs than before. Regulation to
ensure financial benefits and exclude risks for patients there-
fore had to increase compared to that in the age of the giants.
For sure, this makes it (too?) easy to put the blame for stag-
nating clinical translation on regulatory agencies.
The venting of such regulatory complaints focuses almost
exclusively on the USA FDA. Clinical trials currently stand out
as a primary concern [61–63]. The FDA requires a significantly
longer trial period than in the EU. Despite the overwhelming
incentives to enter the dominant USA medical market, many
companies instead opt to move first to overseas markets to
receive initial product approvals. The key advantage to this
strategy is that a new device or drug can first receive
a European CE mark, certifying product human safety but
not always clinical effectiveness, and allowing market author-
ization and entry with required post-market effectiveness sur-
veillance [64]. Clinical trials in this case are simultaneous with
marketing. By contrast, the FDA requires successful trials prov-
ing both safety and efficacy before market certification for any
novel device; new trials are not always required for certain
medical devices similar to appropriate predicates already
approved for market (i.e. FDA 510k pathway). Certainly, inher-
ent public dangers lurk for device/products that are unreliable
or defective; hence, statistical clinical evidence must address
such risks. Product safety might be sacrificed for speed but
with a recognized higher risk to patients. The FDA is clearly
risk-averse and a safety-driven protector of patient interests. In
response to complaints and pressure from US Congress, the
FDA has instead created an expedited access pre-market
approval program for select medical devices that addresses
serious patient medical conditions lacking other viable treat-
ment options [65]. FDA’s response to criticism has been to
increase new application approval rates. Approval rates for
devices increased by 12% in 2015, and an overall 30% increase
from 2012 [66]. In a similar vein, the EU has not been exempt
from the same criticism. Regulations that are over 20 years old
are currently undergoing analysis for reform. Professional
medical organizations are attempting to influence the legisla-
tive process for increased safety and a more streamlined test-
ing and approval system [67–69].
Themedical technology innovation relationship between aca-
demia and industry is tight, and often steered by industry with its
greater financial possibilities. Yet, academia and industry partner-
ships seldom start from de novo partnering: the academic desire
to publish as soon as innovation is evident is orthogonal to the
industrial requirement for exclusivity provided by patenting and
non-disclosure [70,71]. Public–private partnerships between
industry and academia are emerging, but only after long discus-
sion about rights and duties of the partners, alien to most
scientists, but a popular intellectual playground for lawyers
[60]. Successful partnering relies on industry becoming more
flexible and willing to work in a risk-filled environment. Equally,
academia must be more willing to reduce their importance
attached to high-impact papers describing new innovation and
endorse the value of first responsibly protecting important dis-
coveries with patents and subsequent downward clinical transla-
tion [68,72].
4. Conclusion
Evaluating BME’s historic contributions over the past 100 years
by dividing it into three time periods as done here yields the
conclusion that current stagnation in the downward clinical
translation of the assets of BME occurs concurrently (Figure 2)
with several academic and societal changes:
● Developments in biomedical engineering are no longer
conducted by mono-disciplinary trained specialist under
the leadership of highly visionary leaders, but by multi-
disciplinary trained specialists.
● Academic reward systems are no longer based on
achievements of a research group with a clearly visible
leader but on individual academic achievements.
● Multi-disciplinary teaching has become the standard in
academia, rather than in-depth mono-disciplinary
education.
● Governmental oversight in the protection of patients
(and preclinical test animals) has become much stricter.
● industry has become an indispensable partner in clinical
translation, with interests that are not always compatible
with those of their academic collaborators.
Figure 2. Academic and societal changes concurrent with the occurrence of the
stagnation in downward clinical translation of BME assets to clinical application
and recent events that may influence the duration of the translational crisis.
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5. Expert opinion
It is impossible to conclude whether the above concurrency
(Figure 2) may be extrapolated to state that these changes are
causative the stagnation of the downward clinical translation of
BME assets [73]. However, it would be within academic tradition
and direct possibility, to start a thorough evaluation of the role of
multi-disciplinary education programs, with as a possible out-
come a return to in-depth, mono-disciplinary programs. Also,
adapting an academic reward and promotion system based on
academic team achievements rather than the current focus on
performance evaluation of individual academicians might con-
tribute to restoring translational balance. De-emphasizing high-
impact publishing as the primary academic research metric
would also facilitate more focus on clinical validation and intel-
lectual property investments required for translation. Model
changes in academic reward/promotional systems originating
in The Netherlands might be a basis for such considerations
[74]. Changing regulatory requirements and their impact on
clinical translation must be addressed by jointly coordinated
strategies from academia and industry, possibly supplemented
by modern internet-based initiatives such as the Patient
Innovation Sharing Solution [75] or the Euro-African Open
Biomedical Engineering e-platform [76] for addressing individual
patients needs. A recent trans-Atlantic consortium of scientists
has provided published recommendations to change regulatory
requirements, based on enrichment principles [77]. Lessening of
governmental oversight and more flexible approaches toward
required animal preclinical validation will require concerted
efforts from academic and industrial stakeholders to improve
downward clinical translation, but is currently at odds with soci-
etal developments [78]. Alternative preclinical validation models
(e.g. 3-D tissue, or in silico models) represent a future path
forward to assert safety and efficacy as an animal substitute,
but not near term. New ways of working with nonprofit founda-
tions, philanthropy, and charity funds have led to focused aca-
demic-industrial partnerships intent on solving urgent medical
problems considered too risky for industry and commercial mar-
ket places. Along these lines, the Dutch Kidney Foundation pre-
sented in 2018 the first prototype of a portable kidney dialysis
system, developed within record time.
5.1. Five-year view
With the population of the world approaching almost 8 billion
people, it is hard to believe that the current crisis in translating
BME assets to clinical application can be attributed to a lack of
sufficiently talented and visionary leaders. However, driven by
their own and patients desperation for treatment, past giants of
clinical translation broke governmental oversight barriers. Such
self-adapted freedom to operate has been solidly declared unde-
sirable, unethical and even illegal worldwide. However, with the
continuing translational crisis, arguments are being raised that its
consequences may exceed the risks associated with the cavalier
behavior of past giants of clinical translation. Lack of ready permis-
sions or routes for clinical translation may compel post facto
seeking of forgiveness for clinical indiscretions in the name of
new medical interventions. In this respect, it remains to be seen
whether medical tourism to access unproven alternative
therapies, or recent transgressions in human gene editing will be
regarded by history as fraud, an exercise in researcher self-
aggrandizement, narcissism and arrogance, trespassing of world-
wide-accepted ethics (as is current judgment), or as an important
stimulus for a new era of downward clinical translation proceeding
at-risk and renegade of societal constraints.
In short, a number of diverse academic and societal
changes are evident that might explain cause and effect for
the current translational crisis in downward clinical translation
of BME assets to clinical application. Simultaneously, the first
signs of academic and societal changes can also be discerned,
including new violations of governmental oversight and
human ethical constraints that may possibly herald the end
of the current clinical translational crisis.
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